Astellas Pharma, Inc. and Regeneron Pharmaceuticals, Inc. have entered into a non-exclusive license agreement that will allow Astellas to use Regeneron’s VelocImmune technology in its internal research programs to discover human monoclonal antibody product candidates. Astellas will pay $20 million upfront and will make as many as five additional annual payments of $20 million. Astellas will also pay royalties on product sales derived from any antibody products discovered using VelocIm...